Background. The study investigates the influence of the length of membrane rupture period among pregnant women with preterm premature rupture of membranes (PPROM) between the 32nd and 34th weeks of gestation on the development of chorioamnionitis and the congenital infection of a newborn. It seeks to ascertain the values of indicators in mother's blood that enable to predict chorioamnionitis and funisitis for mothers, and congenital infection for newborns.Materials and methods. A retrospective study of case records of women with PPROM at 32 (32 w. + 0 d)-34 (33 w. + 6 d) weeks of gestation and their newborns was performed. Two comparative groups were made: 1) of women who had funisitis and / or chorioamnionitis with or without deciduitis and 2) of women having no proved inflammation (according to the results of histological examination of placentae). Analogically, comparative groups were made of their newborns: those who had diagnosis of congenital infection and those who had no infection. The duration of membrane rupture period and the blood markers were investigated in all the groups.Results. The study included 135 women. Duration of the membrane rupture period lasted 85.17 ± 84.72 hrs in the group of women who had histological inflammation, and 40.06 ± 56.57 hrs in the group with no inflammation, P = 0.01, AUC = 0.735; the critical membrane rupture period value for developing intrauterine infection by the Youden index was 43.7 hrs. The corresponding maternal CRP values (mg/l) were 25.85 ± 40.27 vs. 5.23 ± 7.88 (P = 0.01, AUC = 0.6), the Youden index 4.6 mg/l. For the mothers of the newborns diagnosed with infection, the duration of the membrane rupture period was 55.95 ± 65.04 hrs, for the mothers of the newborns without congenital infection it was 40.25 ± 73.71 hours. Respectively, CRP values for the mothers of newborns averaged 12.25 ± 22.14 mg/l vs. 4.8 ± 4.82 mg/l (P = 0.005).Conclusions. Longer membrane rupture period and higher maternal CRP are correlated with inflammatory changes in the placenta and umbilical cord, thus they can be used as the prognostic indicators of intrauterine infection. When the duration of the membrane rupture period lasts ≥44 hrs, the risk of chorioamnionitis and funisitis increases five times; when the maternal serum CRP is higher than 5 mg/l, funisitis / chorioamnionitis is twice more frequent than at lower than 5 mg/l CRP values.
Visame pasaulyje, tiek ir Lietuvoje, kasmet auga pirmakarčių gimdyvių amžiaus vidurkis, kuris, tyrimų duomenimis, gali būti susijęs su padidėjusia nėštumo bei gimdymo rizika ir padidėjusiu naujagimių sergamumu. Mūsų tyrimo tikslas buvo palyginti vyresnio amžiaus (>35 metai) ir optimalaus amžiaus pirmakarčių gimdyvių (20-29 metų) nėštumo eigą, gimdymo ypatumus bei naujagimių būkles. Retrospektyvinio tyrimo metu buvo išanalizuota 209 moterų, 2015 metais gimdžiusių VMKL, gimdymo ir naujagimių istorijos. Buvo palyginti vyresnio (>35 metų) (tiriamoji grupė- 109 pacienčių) ir optimalaus amžiaus (20-29 metų) (kontrolinė grupė- 100 pacienčių) pirmakarčių gimdymo ir naujagimių istorijų duomenys. Aprašomosios statistikos pagrindu atliktas pirminis kiekybinių duomenų apdorojimas. Statistiškai patikimais laikyti tie atvejai, kai p<0,05. Surinkti duomenys suvesti ir apdoroti, naudojant SPSS 23.0 programinį paketą. Vidutinis tiriamosios grupės amžius- 37,4±0,22 metai, kontrolinės grupės- 25,35±0,23 metai. Tiriamosios grupės sergamumas su nėštumu susijusiomis ligomis nesiskyrė nuo kontrolinės grupės, tačiau vyresnių pirmakarčių nėštumas buvo 2,6 kartais dažniau užbaigtas cezario pjūvio operacijos būdu, o gimdymas natūraliais takais truko statistiškai patikimai ilgiau nei jaunesnių pirmakarčių. Naujagimių būklė, įgimtų formavimosi ydų dažnis ir sergamumas tiriamojoje ir kontrolinėje grupėse statistiškai reikšmingai nesiskyrė.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.